Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)

K. Newbold, P. Schoeffski, B. Hasan, L. D. Locati, Y. Godbert, C. de la Fouchardiere, L. Bastholt, M. Fassnacht, N. Reed, Y. Lalami, C. Chougnet, C. Schvartz, E. Kapiteijn, M. J. Schlumberger, W. Sents, N. Sauve, S. Leboulleux

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number1919P
JournalAnnals of Oncology
Issue numberSuppl. 4
Pages (from-to)S1087-S1088
Publication statusPublished - 1. Sept 2020
EventESMO Virtual Congress -
Duration: 19. Sept 202018. Oct 2020


ConferenceESMO Virtual Congress

Cite this